肿瘤坏死因子阻滞剂与强直性脊柱炎的结构重塑：何为现实，何为虚幻？
Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction?
作者信息
Schett Georg, Landewé Robert, van der Heijde Désirée
出版信息
Ann Rheum Dis. 2007 Jun;66(6):709-11. doi: 10.1136/ard.2007.071159.
Abstract
A delineation of the differences in pathology between AS and RA
摘要
强直性脊柱炎与类风湿关节炎病理差异的描述
相似文献
1
Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction?肿瘤坏死因子阻滞剂与强直性脊柱炎的结构重塑：何为现实，何为虚幻？
Ann Rheum Dis. 2007 Jun;66(6):709-11. doi: 10.1136/ard.2007.071159.
2
Just released from the ASAS factory! First steps towards a disease activity score for ankylosing spondylitis.刚从脊柱关节炎协会（ASAS）工厂发布！迈向强直性脊柱炎疾病活动评分的第一步。
Ann Rheum Dis. 2009 Jan;68(1):1-2. doi: 10.1136/ard.2008.097774.
3
Anti-TNF-alpha therapy for ankylosing spondylitis--a specific or nonspecific treatment?抗肿瘤坏死因子-α治疗强直性脊柱炎——一种特异性还是非特异性治疗？
N Engl J Med. 2002 May 2;346(18):1399-400. doi: 10.1056/NEJM200205023461811.
4
Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?肿瘤坏死因子阻滞剂能否抑制强直性脊柱炎未来结构损伤的进展？
Ann Rheum Dis. 2008 Sep;67(9):1354. doi: 10.1136/ard.2007.082537.
5
TNF-blocking therapy in rheumatoid arthritis and ankylosing spondylitis: why is cost-effectiveness a major issue?类风湿关节炎和强直性脊柱炎中的肿瘤坏死因子阻断疗法：为何成本效益是一个主要问题？
Curr Rheumatol Rep. 2005 Aug;7(4):254-8. doi: 10.1007/s11926-005-0032-9.
6
Ankylosing Spondylitis Treatment after First Anti-TNF Drug Failure.首次抗TNF药物治疗失败后的强直性脊柱炎治疗
Isr Med Assoc J. 2018 Feb;20(2):119-122.
7
How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?强直性脊柱炎应多早在肿瘤坏死因子阻滞剂治疗？
Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv61-4. doi: 10.1136/ard.2005.042432.
8
The inadequate anti-tumour necrosis factor (anti-TNF) therapy in patients with ankylosing spondylitis.强直性脊柱炎患者抗肿瘤坏死因子（抗TNF）治疗不足。
Rheumatol Int. 2010 Nov;30(12):1689-90. doi: 10.1007/s00296-009-1283-y. Epub 2009 Dec 15.
9
Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis.英夫利昔单抗可抑制类风湿关节炎和强直性脊柱炎患者循环破骨细胞前体细胞的骨吸收。
Ann Rheum Dis. 2008 May;67(5):620-4. doi: 10.1136/ard.2007.076711. Epub 2007 Aug 24.
10
Anti-tumour necrosis factor therapy in ankylosing spondylitis. A need for guidelines.强直性脊柱炎的抗肿瘤坏死因子治疗。需要指南。
Rheumatology (Oxford). 2003 Mar;42(3):490. doi: 10.1093/rheumatology/keg113.
引用本文的文献
1
Comparison of radiological and functional outcomes of conservative treatment with teriparatide and denosumab in thoracolumbar osteoporotic vertebral fracture.保守治疗联合特立帕肽与地舒单抗治疗胸腰椎骨质疏松性骨折的影像学和功能结局比较。
Osteoporos Int. 2024 May;35(5):795-804. doi: 10.1007/s00198-024-07025-4. Epub 2024 Jan 23.
2
Extracellular PPM1A promotes mineralization of osteoblasts differentiation in ankylosing spondylitis via the FOXO1A-RUNX2 pathway.细胞外 PPM1A 通过 FOXO1A-RUNX2 通路促进强直性脊柱炎成骨细胞分化的矿化。
J Cell Mol Med. 2023 Mar;27(5):650-658. doi: 10.1111/jcmm.17685. Epub 2023 Feb 9.
3
Clinical and Radiological Features Predicting Intervertebral Autofusion after Successful Antibiotic Therapy in Pyogenic Vertebral Osteomyelitis.预测化脓性椎体骨髓炎抗生素治疗成功后椎间自体融合的临床和影像学特征
Diagnostics (Basel). 2021 Jul 27;11(8):1349. doi: 10.3390/diagnostics11081349.
4
The Influence of Adalimumab and Cyclosporine A on the Expression Profile of the Genes Related to TGF Signaling Pathways in Keratinocyte Cells Treated with Lipopolysaccharide A.阿达木单抗和环孢素A对经脂多糖A处理的角质形成细胞中与转化生长因子信号通路相关基因表达谱的影响。
Mediators Inflamm. 2020 Jul 26;2020:3821279. doi: 10.1155/2020/3821279. eCollection 2020.
5
Effect of tumor necrosis factor inhibition on spinal inflammation and spinal ankylosis in SKG mice.肿瘤坏死因子抑制对 SKG 小鼠脊髓炎症和脊柱强直的影响。
Sci Rep. 2019 Nov 29;9(1):18000. doi: 10.1038/s41598-019-54549-5.
6
A Jack of All Trades: Impact of Glucocorticoids on Cellular Cross-Talk in Osteoimmunology.多面手：糖皮质激素对骨免疫学中细胞串扰的影响。
Front Immunol. 2019 Oct 17;10:2460. doi: 10.3389/fimmu.2019.02460. eCollection 2019.
7
The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis.IL-23-IL-17 通路作为轴性脊柱关节炎的治疗靶点。
Nat Rev Rheumatol. 2019 Dec;15(12):747-757. doi: 10.1038/s41584-019-0294-7. Epub 2019 Sep 24.
8
Altered expression of microRNAs targeting Dkk-1 in peripheral blood mononuclear cells of patients with ankylosing spondylitis.强直性脊柱炎患者外周血单个核细胞中靶向 Dickkopf-1 的微小核糖核酸表达改变。
Cent Eur J Immunol. 2019;44(1):59-64. doi: 10.5114/ceji.2019.84018. Epub 2019 Apr 15.
9
Evaluation of destruction in a collagen-induced arthritis rat model: Bony spur formation.胶原诱导性关节炎大鼠模型中破坏情况的评估：骨赘形成。
Exp Ther Med. 2017 Sep;14(3):2563-2567. doi: 10.3892/etm.2017.4817. Epub 2017 Jul 19.
10
Relationship between inflammation, bone destruction, and osteoproliferation in the HLA-B27/human β2 -microglobulin-transgenic rat model of spondylarthritis.脊柱关节炎的HLA - B27/人β2 -微球蛋白转基因大鼠模型中炎症、骨破坏与骨增殖之间的关系
Arthritis Rheum. 2012 Oct;64(10):3210-9. doi: 10.1002/art.34600.
本文引用的文献
1
Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis.血清基质金属蛋白酶3是强直性脊柱炎患者结构损伤进展的独立预测指标。
Arthritis Rheum. 2007 Jun;56(6):1846-53. doi: 10.1002/art.22589.
2
Dickkopf-1 is a master regulator of joint remodeling.Dickkopf-1是关节重塑的主要调节因子。
Nat Med. 2007 Feb;13(2):156-63. doi: 10.1038/nm1538. Epub 2007 Jan 21.
3
Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes.依那西普联合甲氨蝶呤治疗后炎症与关节破坏之间的脱节：依那西普和甲氨蝶呤影像学及患者预后试验结果
Arthritis Rheum. 2006 Oct;54(10):3119-25. doi: 10.1002/art.22143.
4
Mechanisms of Disease: the link between RANKL and arthritic bone disease.疾病机制：RANKL与关节炎性骨病之间的联系。
Nat Clin Pract Rheumatol. 2005 Nov;1(1):47-54. doi: 10.1038/ncprheum0036.
5
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.阿达木单抗治疗强直性脊柱炎患者的疗效和安全性：一项多中心、随机、双盲、安慰剂对照试验的结果
Arthritis Rheum. 2006 Jul;54(7):2136-46. doi: 10.1002/art.21913.
6
Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study.英夫利昔单抗治疗后强直性脊柱炎患者脊柱炎症显著减轻：一项多中心、随机、双盲、安慰剂对照磁共振成像研究的结果
Arthritis Rheum. 2006 May;54(5):1646-52. doi: 10.1002/art.21790.
7
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.分化的成骨细胞中的经典Wnt信号传导控制破骨细胞分化。
Dev Cell. 2005 May;8(5):751-64. doi: 10.1016/j.devcel.2005.02.017.
8
Magnetic resonance imaging for accelerated assessment of drug effect and prediction of subsequent radiographic progression in rheumatoid arthritis: a study of patients receiving combined anakinra and methotrexate treatment.磁共振成像用于类风湿关节炎药物疗效的加速评估及后续影像学进展预测：一项关于接受阿那白滞素与甲氨蝶呤联合治疗患者的研究
Ann Rheum Dis. 2005 Oct;64(10):1503-6. doi: 10.1136/ard.2005.038018. Epub 2005 Mar 18.
9
The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis.类风湿关节炎患者疾病活动度与放射学进展的关系：一项纵向分析。
Arthritis Rheum. 2004 Jul;50(7):2082-93. doi: 10.1002/art.20350.
10
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.在接受甲氨蝶呤联合治疗的活动性类风湿关节炎患者中，使用阿达木单抗（一种人抗肿瘤坏死因子单克隆抗体）治疗的影像学、临床及功能转归：一项随机、安慰剂对照、为期52周的试验。
Arthritis Rheum. 2004 May;50(5):1400-11. doi: 10.1002/art.20217.
Zotero 插件